FDA Brief

Warning letters Drugs

FDA warning letter to

Babikian Healthcare Products CJSC

High riskIssued Sep 21Posted Sep 29Center for Drug Evaluation and Research (CDER)

FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

What happened

FDA reviewed records Babikian submitted after FDA's August 12, 2025 request for records under section 704(a)(4) of the FD&C Act. FDA said the firm did not test each incoming component's identity, relied on supplier certificates without verifying them, and lacked finished-product tests for identity, strength, impurities, and microorganisms. FDA also said the quality unit failed to ensure procedures, batch records, stability data, and authority.

What FDA found

  1. The firm did not test the identity of each incoming component before use and did not verify its suppliers' test results at appropriate intervals.

    21 CFR 211.84(d)(1) & 211.84(d)(2)
  2. The firm did not test each finished batch for identity and strength of active ingredients, impurities, and objectionable microorganisms before release.

    21 CFR 211.165(a) and 211.165(b)
  3. The quality unit did not ensure written production and process control procedures, qualification of a system producing a drug component, complete batch records, stability data, and adequate authority and procedures.

    21 CFR 211.22; 21 CFR 211.100(a); 21 CFR 211.188; 21 CFR 211.137(a); 21 CFR 211.22(a) & 211.22(d)
  4. A second Babikian establishment listed as manufacturer of record for U.S. shipments was not registered with FDA as a drug establishment.

    section 510(i) of the FD&C Act and 21 CFR 207.17(a)

What FDA wants

FDA tells the company to send a written response within 15 business days to CDER-OC-OMQ-Communications@fda.hhs.gov, identify FEI 3027526825, address root causes and corrective actions, and engage a qualified CGMP consultant.

Who should pay attention

  • U.S. companies importing or distributing OTC drugs made by this firm
  • brands using Babikian as a contract manufacturer or manufacturer of record
  • buyers relying on supplier certificates of analysis for active ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk